2/7/2023  5:30:17 PM Chg. -0.0400 Volume Bid7:40:00 AM Ask7:40:00 AM Market Capitalization Dividend Y. P/E Ratio
1.4700CHF -2.65% 72,387
Turnover: 108,579.4400
1.6200Bid Size: 5 1.5600Ask Size: 6,622 48.23 mill.CHF 0.00% -

Business description

After the merger with Cytos Biotechnology Ltd in 2016 the Kuros Biosciences Ltd is developing innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), Kuros has developed a pipeline of products based upon its proprietary technology platforms. These platforms were developed from work carried out at ETHZ, at the University of Zürich and at the California Institute of Technology (CalTech). In addition, in early 2017 Kuros acquired Xpand Biotechnology to gain access to its MagnetOs family of bone graft substitutes and the associated surface science technology. Kuros has attractive commercial prospects in key market segments as well as an EU hub for future clinical and distribution operations. In June 2017 Kuros Biosciences has received CE certification for its novel dural sealant, Neuroseal®. The CE certification allows for the commercialization of the product anywhere in the European Economic Area. MagnetOs is approved for sale in the EU for orthopedic, spine and dental applications, and in the US for posterolateral spinal fusion. In addition, MagnetOs Putty is approved for sale as an autograft extender in posterolateral spine in US. Kuros Biosciences Ltd is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands.
 

Management board & Supervisory board

CEO
Prof. Joost de Bruijn
Management board
Michael Grau, Dr. Alistair Irvine, Dr. Pascal Longlade, Dr. Philippe Saudan, Frank-Jan van der Velden
Supervisory board
Prof. Dr. Clemens van Blitterswijk, Chris Fair, Dr. Scott P. Bruder, Leanna Caron, Oliver Walker, Prof. Joost de Bruijn
 

Company data

Name: Kuros Biosciences AG
Address: Wagistraße 25,CH-8952 Schlieren
Phone: +41-44-733-4747
Fax: +41-44-733-4740
E-mail: info@kurosbio.com
Internet: www.kuros.ch
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 49.30%
IPO date: -

Investor relations

Name: Hans Herklots
IR phone: +41-79-5987149
IR Fax: +41-44-733-4740
IR e-mail: hherklots@lifesciadvisors.com

Company calendar

CW 11 | 3/14/2023 4th Quarter/Annual Report
CW 19 | 5/8/2023 General Shareholder Meeting
CW 32 | 8/9/2023 Interim Report 2nd Quarter/6 Months
 

Main Shareholders

Freefloat
 
49.30%
Incubation B.V. und Aldabra B.V
 
25.60%
CS (CH Small Cap Switzerland Equity Fund)
 
11.60%
APO Asset Management
 
4.60%
LSP V Coöperatieve U.A.
 
4.60%
Banque Pictet & Cie SA
 
4.30%